| scholarly article | Q13442814 |
| P50 | author | Elizabeth Simpson | Q15968540 |
| Steven H Sacks | Q60712059 | ||
| P2093 | author name string | Julian Dyson | |
| Stipo Jurcevic | |||
| Conrad A Farrar | |||
| Maggie Millrain | |||
| James E Marsh | |||
| Roseanna E G Hargreaves | |||
| Nicola J Monk | |||
| P2860 | cites work | CD40 AND CD154 IN CELL-MEDIATED IMMUNITY | Q22255634 |
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Phenotypic analysis of antigen-specific T lymphocytes | Q28290058 | ||
| Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity | Q33703237 | ||
| Current trends in transplant immunology | Q33716996 | ||
| Transplantation tolerance-where do we stand? | Q33764678 | ||
| The role of T cell apoptosis in transplantation tolerance. | Q34046810 | ||
| Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases | Q34096275 | ||
| The role of peripheral T-cell deletion in transplantation tolerance | Q34262660 | ||
| An H-YDb epitope is encoded by a novel mouse Y chromosome gene | Q34409498 | ||
| The male-specific histocompatibility antigen, H-Y: a history of transplantation, immune response genes, sex determination and expression cloning | Q34425408 | ||
| CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates | Q34433847 | ||
| Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis | Q36028683 | ||
| In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions | Q36362569 | ||
| gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory | Q36363299 | ||
| Resistance of Fc receptor- deficient mice to fatal glomerulonephritis. | Q37387592 | ||
| T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state | Q38173933 | ||
| Predominant role for C5b-9 in renal ischemia/reperfusion injury. | Q40437461 | ||
| Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis | Q40779426 | ||
| Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules | Q40897983 | ||
| The role of CD40 ligand in costimulation and T-cell activation | Q41332099 | ||
| Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. | Q54073234 | ||
| Failure of combined costimulatory blockade in animal transplant model | Q56906306 | ||
| Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner | Q56906395 | ||
| Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways | Q56908985 | ||
| CD40 ligand-independent B cell activation revealed by CD40 ligand-deficient T cell clones: evidence for distinct activation requirements for antibody formation and B cell proliferation | Q61268446 | ||
| Cutting Edge: Anti-CD154 Therapeutic Antibodies Induce Infectious Transplantation Tolerance | Q61651670 | ||
| T cells are just dying to accept grafts | Q63408399 | ||
| A cell culture model for T lymphocyte clonal anergy | Q67299314 | ||
| Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice | Q68074352 | ||
| Mice deficient for the CD40 ligand | Q72610555 | ||
| Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand | Q73401367 | ||
| Reply to failure of combined costimulatory blockade in animal transplant model | Q73401375 | ||
| Monoclonal antibody therapies-a 'constant' threat to cancer | Q73606520 | ||
| Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning | Q73910639 | ||
| Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction | Q74191513 | ||
| The allogeneic T and B cell response is strongly dependent on complement components C3 and C4 | Q74623666 | ||
| Graft tolerance: a duel of two signals | Q77890098 | ||
| Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates | Q77890140 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 1275-1280 | |
| P577 | publication date | 2003-09-14 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade | |
| P478 | volume | 9 |
| Q93368314 | Ablation of interferon regulatory factor 4 in T cells induces "memory" of transplant tolerance that is irreversible by immune checkpoint blockade |
| Q34870978 | An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig. |
| Q39265882 | Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation |
| Q34166913 | Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates. |
| Q51797602 | Blockade of the PD-1/PD-1L pathway reverses the protective effect of anti-CD40L therapy in a rat to mouse concordant islet xenotransplantation model. |
| Q90154642 | CD11b is a novel alternate receptor for CD154 during alloimmunity |
| Q35318823 | CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes |
| Q36339318 | CD40/CD154 blockade inhibits dendritic cell expression of inflammatory cytokines but not costimulatory molecules |
| Q42876261 | CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase |
| Q37801909 | Co-stimulation blockade as a new strategy in kidney transplantation: benefits and limits. |
| Q42820665 | Combined Application of Blocking Antibodies and MicroRNA Interference in Inhibiting CD44 Expression |
| Q34361871 | Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy |
| Q34187594 | Costimulatory pathways in transplantation |
| Q59387560 | Critical role of the calpain/calpastatin balance in acute allograft rejection |
| Q37316082 | Depleting T-cell subpopulations in organ transplantation |
| Q35223846 | Differential outcomes in prediabetic vs. overtly diabetic NOD mice nonmyeloablatively conditioned with costimulatory blockade |
| Q38515353 | Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance. |
| Q56900682 | Enhancement of T cell activation by immobilized hu5C8 (anti-CD40L) monoclonal antibody |
| Q37019142 | Fates of CD4+ T cells in a tolerant environment depend on timing and place of antigen exposure |
| Q50948280 | Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection. |
| Q38751293 | First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 6: patient selection for pilot clinical trials of islet xenotra |
| Q36689232 | From current immunosuppressive strategies to clinical tolerance of allografts |
| Q83940098 | From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis |
| Q37755305 | Functional dichotomy of NK cells in organ transplantation |
| Q45732570 | Gene transfer of human CD40Ig does not prevent rejection in a non-human primate kidney allotransplantation model |
| Q34015403 | Germinal center B cell depletion diminishes CD4+ follicular T helper cells in autoimmune mice |
| Q36838049 | Glucocorticoid-induced TNFR-related protein stimulation reverses cardiac allograft acceptance induced by CD40-CD40L blockade |
| Q36540470 | IL-10 from marginal zone precursor B cells controls the differentiation of Th17, Tfh and Tfr cells in transplantation tolerance |
| Q34873028 | IL-6 induced by Staphylococcus aureus infection prevents the induction of skin allograft acceptance in mice |
| Q46009385 | Indefinite mouse heart allograft survival in recipient treated with CD4(+)CD25(+) regulatory T cells with indirect allospecificity and short term immunosuppression. |
| Q57983040 | Inducing Tolerance to a Soluble Foreign Antigen by Encapsulated Cell Transplants |
| Q54297363 | Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing. |
| Q45884021 | Induction of donor-specific tolerance in sublethally irradiated recipients by gene therapy |
| Q37075945 | Inhibition of CD8+ T cell-derived CD40 signals is necessary but not sufficient for Foxp3+ induced regulatory T cell generation in vivo |
| Q36001633 | Interleukin-10 From Marginal Zone Precursor B-Cell Subset Is Required for Costimulatory Blockade-Induced Transplantation Tolerance |
| Q34309101 | Intermittent antibody-based combination therapy removes alloantibodies and achieves indefinite heart transplant survival in presensitized recipients. |
| Q30577194 | Laminins affect T cell trafficking and allograft fate |
| Q38742520 | Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier |
| Q38316361 | Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade. |
| Q35675449 | Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates |
| Q38445344 | Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance |
| Q37259532 | OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade |
| Q54283965 | Rapamycin and CTLA4Ig synergize to induce stable mixed chimerism without the need for CD40 blockade. |
| Q37691776 | Regulatory T cells in transplantation: does extracellular adenosine triphosphate metabolism through CD39 play a crucial role? |
| Q26769878 | Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement |
| Q33947967 | Requirements for induction and maintenance of peripheral tolerance in stringent allograft models |
| Q37610449 | Role of IDO in organ transplantation: promises and difficulties |
| Q80015991 | Simultaneous deletion of MyD88 and Trif delays major histocompatibility and minor antigen mismatch allograft rejection |
| Q37043717 | Special regulatory T-cell review: Regulation of immune responses--examining the role of T cells |
| Q37400003 | Strategic nonmyeloablative conditioning: CD154:CD40 costimulatory blockade at primary bone marrow transplantation promotes engraftment for secondary bone marrow transplantation after engraftment failure |
| Q38837473 | T Cell Cosignaling Molecules in Transplantation |
| Q36251293 | T cell tolerance induced by therapeutic antibodies |
| Q33920121 | T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway |
| Q36568502 | TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance |
| Q37562436 | TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts |
| Q38150101 | Targeting co-stimulatory pathways: transplantation and autoimmunity |
| Q35596631 | The CD40/CD40L costimulatory pathway in inflammatory bowel disease |
| Q36984472 | The classical complement pathway in transplantation: unanticipated protective effects of C1q and role in inductive antibody therapy |
| Q36530319 | The last 5 years of basic science investigation in transplant immunology |
| Q61651660 | The new immunosuppression: just kill the T cell |
| Q38013049 | The role of complement in the early immune response to transplantation. |
| Q37474964 | Translating costimulation blockade to the clinic: lessons learned from three pathways |
| Q37359067 | Transplant acceptance following anti-CD4 versus anti-CD40L therapy: evidence for differential maintenance of graft-reactive T cells |
| Q36406567 | Transplant tolerance: models, concepts and facts |
| Q35887823 | Transplantation of hematopoietic stem cells for induction of unresponsiveness to organ allografts |
| Q55221876 | Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity. |
Search more.